Pomerantz LLP is investigating Sellas Life Sciences Group for possible securities fraud after the company delayed releasing results from a critical phase 3 clinical trial for its drug Galinpepimut-S. The trial reached a key milestone with the 80th patient death on August 28, 2026, which should have prompted immediate disclosure of results. Instead, Sellas withheld the information, causing its stock to fall 13.15% that day. The investigation will determine if Sellas and its executives engaged in unlawful practices, impacting investor trust and potentially leading to legal action.
The investigation into Sellas Life Sciences Group follows concerns about delayed clinical trial results. For readers following the health sector, here is Pluang's market snapshot as of Sep 25, 2026 04:41 WIB: out of 100 priced US health stocks, 38 rose and 62 fell. Notable movers include OSCR at USD 28.86 with a 5.47% decline and a typical hold time of 14 days, CRSP at USD 55.93 down 5.25% with a 77-day hold time, and RXRX at USD 3.89 up 5.14% with a 22-day hold time. Pluang order activity shows mixed sentiment with OSCR slightly more sold and CRSP and RXRX fully bought.
The Schwab U.S. Dividend Equity ETF (SCHD) is a popular choice for investors seeking consistent dividend growth and a solid yield. The author, who holds a long position in SCHD, enhances income by employing options selling strategies, including cover...
TD SYNNEX posted a record-breaking quarter in Q3 2026 with earnings and revenue surpassing expectations, driven by strong growth in its Hyve Solutions segment and AI infrastructure demand. Despite this, the stock dropped nearly 9% due to a nearly $1 ...
A crypto whale transferred 6,000 Ether (ETH), worth approximately $16.1 million, to five major cryptocurrency exchanges: OKX, Kraken, Gate, Bybit, and Binance. This large transfer places a significant amount of ETH on trading platforms, suggesting th...
Warren Buffett increased his stake in homebuilder Lennar to over 10% immediately after the company missed earnings and lowered its full-year delivery forecast. Despite Lennar's recent weak quarter, Buffett's move signals confidence in the long-term h...
TRON has exceeded $30 trillion in total transaction volume, marking its evolution into a high-throughput settlement network. Daily transactions exceed $30 billion, supported by over 405 million users and 15.6 billion processed transactions, mainly dr...
